Evidence map›Paper›PMID 40171868›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Artificial Intelligent-Enhanced Metabolite Profiling for Intraoperative IDH1 Genotyping in Glioma Using an Orthogonally Responsive SERS Probe.

Hang Yin, Xin Zhang, Zheng Zhao, Chong Cao, Minhua Xu, Suhongrui Zhou, Tian Xuan, Ziyi Jin, Limei Han, Yang Fan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hang YinMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Xin ZhangDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China.
Zheng ZhaoSchool of Information Science and Technology, Fudan University, Shanghai, 200433, China.
Chong CaoDepartment of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.
Minhua XuMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Suhongrui ZhouMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Tian XuanMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Ziyi JinMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Limei HanArtificial Intelligence Innovation and Incubation Institute, Fudan University, Shanghai, 200433, China.
Yang FanMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Cong WangMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Xiao ZhuMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Ying MaoDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China.
Jinhua YuSchool of Information Science and Technology, Fudan University, Shanghai, 200433, China.
Cong LiMOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, School of Pharmacy, Fudan University, Shanghai, 201203, China.ORCID https://orcid.org/0000-0001-7731-8031

Funding

Greater Bay Area Institute of Precision MedicineNational Key Research and Development Program of China 2023YFA1801200National Key Research and Development Program of China 2023YFF0714200National Natural Science Foundation of China 82202224National Natural Science Foundation of China 82204544National Natural Science Foundation of China 82227806National Natural Science Foundation of China 92159304National Science Fund for Distinguished Young Scholars 82025019Science and Technology Commission of Shanghai Municipality 23J21901700Science and Technology Commission of Shanghai Municipality 23TS1401100Shanghai Health Commission Emerging Cross Disciplinary Research Project 2022JC003Shanghai Rising-Star Program 23QA1407700
6 · The paper itself

Abstract

Intraoperative identification of the isocitrate dehydrogenase type 1 (IDH1) genotype, a key molecular marker in glioma, is essential for optimizing surgical strategies and tailoring post-surgical treatments. However, current clinical practices lack effective methods for real-time IDH1 genotype detection during surgery. Here, a novel strategy is proposed for intraoperative IDH1 genotype identification by simultaneously measuring two redox-related metabolites. A surface-enhanced Raman scattering (SERS) probe is developed to detect glutathione and hydrogen peroxide concentrations through orthogonally responsive Raman signals. Additionally, a deep learning algorithm is implemented, leveraging 2D Raman spectra transformation and multi-task learning to enhance measurement speed and accuracy. This AI-assisted SERS approach can identify the IDH1 genotype in glioma patients within 7 min. In a cohort of 31 glioma patients, the system achieved an area under the receiver operating characteristic curve of 0.985 for accurate IDH1 genotype differentiation. This study holds significant promise for refining surgical decision-making and personalizing post-surgical treatments by enabling rapid intra-operative molecular biomarker identification.

Indexed as

Artificial IntelligenceBrain NeoplasmsGliomaIsocitrate DehydrogenaseSpectrum Analysis, RamanBiomarkers, TumorFemaleGenotypeHumansMaleBiomarkers, TumorIDH1 protein, humanIsocitrate Dehydrogenasegliomagold nanoprobesintraoperative IDH genotypingmolecular imagingsurface‐enhanced Raman scattering (SERS)

Identifiers

PMID40171868
PMCPMC12245123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.